Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACA trial of timing, fasting, and low-carbohydrate diet with alpelisib
2021-000845-42Phase 2Suspended
- Sponsor
- Clinical Center Group
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alpelisib in breast cancer (2 arms), sponsored by Clinical Center Group. Primary endpoint: Exposure-adjusted incidence rate of grade 3 or 4 hyperglycemia. Started May 2022; status: suspended.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-000845-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000845-42.